Hereditary Angioedema Market By Drug Class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, and Others), By Route of Administration (Subcutaneous, Intravenous, and Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and By Region - Trends, Analysis and Forecast till 2030

Expanding the scope of research and development

Expanding R&D endeavors by prominent industry participants and amplified backing from diverse governmental and healthcare regulatory agencies involved in managing hereditary angioedema are principal drivers propelling the market's expansion. For example, the FDA in the United States authorized CSL Behring's Haegarda (C1-esterase inhibitor) in 2017. This medication is prescribed for routine prophylaxis to prevent attacks of hereditary angioedema in adult and adolescent patients. Shire plc's TAKHZYRO (lanadelumab injectable) was approved by Health Canada in September 2018 for treating hereditary angioedema (HAE) in adults and adolescents 12 years of age and older.